Aptamers for protection against viral infections

The Li Lab, in collaboration with the Miller Lab, has made progress with using aptamers as therapeutics to prevent infections like COVID-19.

A high binding affinity COVID-19 (C19HBA) aptamer was compared to commercial monoclonal antibodies in a pre-clinical study. Results show that testing has been successful in protected the mouse model used in the pre-clinical study from infection as effectively as commercial monoclonal antibodies.

For the story published by McMaster University, click HERE.

The aptamer research described above is partially funded by Zentek Ltd., a technology development and commercialization company. We’re thankful for the collaboration with both the Miller Lab and Zentek Ltd.

For a news release by Zentek Ltd. on initial testing, click HERE.

For a news release by Zentek Ltd. on the aptamer technology platform, click HERE.

For a news release by Zentek Ltd. on the results of the pre-clinical study, click HERE.

Bookmark the permalink.